New drug SKB264 takes on tough breast cancer in Late-Stage trial

NCT ID NCT05347134

Ongoing Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a new chemotherapy drug called SKB264 against standard chemotherapies in 254 people with advanced triple-negative breast cancer that has worsened after at least two prior treatments. The main goal is to see if SKB264 can delay cancer growth longer than the usual options. Participants receive either SKB264 or a standard chemo chosen by their doctor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKB264 (a chemotherapy drug)
What this could lead to: If successful, this could offer a new treatment option for people with advanced triple-negative breast cancer who have run out of standard therapies.
What could go wrong: This is a Phase 3 trial, but results are not yet available. The drug may not improve survival or could cause serious side effects like other chemotherapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Science

Beijing, Beijing Municipality, 100021, China
Jiangsu Province Hospital

Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.